Zoya Demidenko: Scholar in Oncology Studies
Zoya Demidenko is a notable researcher associated with the Department of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she conducted research at the National Institutes of Health and New York Medical College, establishing a strong background in life science investigation.
Demidenko's scholarly work encompasses a number of key areas, encompassing the PI3K/AKT/mTOR signaling pathway, cellular cycle regulation, cellular aging, and tumor science. Currently, she has co-authored over 46 peer-reviewed publications, which have garnered more than 4,100 references — a testament to the impact of her research.
Among her most significant achievements involves understanding the mechanisms of biological cell aging. Her work demonstrated that when the cellular division cycle is arrested while cellular growth proceeds, cells undergo senescence. Importantly,
Zoya Demidenko demonstrated that this shift can be pharmacologically suppressed using substances such as mTOR inhibitors.
Zoya Demidenko has furthermore added considerably to tumor management investigation, particularly in the field of cyclotherapy — a strategy designed to shielding normal tissue from anticancer drugs while leaving malignant cells vulnerable. This method offers major hope for reducing the toxic effects of cancer treatment.
Across her professional journey, Demidenko has worked with prominent researchers globally, such as Dr. Mikhail Blagosklonny. Her work is published in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33,
Zoya Demidenko stands as a influential voice in modern biomedical science, with her results keep to influence our understanding of the way cells age, interact with therapy, and how malignant disease may be better treated.
https://uk.linkedin.com/in/berezutskayahttps://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6fqfq45eme2/
Dienstag, 24. März 2026 12:43